The restructuring is only the latest round of layoffs to hit Arbutus, after the company shed 40% of its staff and cut back on ...

Incorporating systems thinking into drug value assessment promises more realistic evaluations of the impact of new therapies, ...

According to a 2024 review, pegylated interferons may offer significant safety, prolonged stability, and fewer toxicity challenges compared to interferons used in the past. However, more research ...

Background and Aim: Current practice guidelines recommend that individuals chronically infected with the hepatitis C virus (HCV) be treated with pegylated interferon plus ribavirin. Ribavirin ...

Thus, the role of other immune responses, including those mediated by natural killer (NK) cells, must be considered in HDV pathogenesis and in treatments with immune-stimulating agents such as ...

Type I interferons (IFNs) play a role in murine PBC; however, little is known regarding their involvement and the role of type II/III IFNs in PBC patients. The aim of this investigation was to explore ...

While the concentration of conventional interferon peaks and then declines rapidly after subcutaneous administration, the serum concentration of pegylated interferon increases gradually and does ...

The interferon (IFN) family of proteins plays key roles in the immune response against viruses and other pathogens. In the context of COVID-19, IFNs have been shown to be key for restraining ...

BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization ...

More recently, pegylated drugs for the treatment of hepatitis ... of Intron-A causes peaks and troughs in blood levels of interferon. In comparison, once-weekly administration of PegIntron ...

The interferon pathway is the first line of defense in viral infection in all mammals, and its induction stimulates broad expression of interferon-stimulated genes (ISGs). In mice and also humans, the ...